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Abstract 
People with schizophrenia typically experience auditory hallucinations or delusions during 
acute episodes. Although effective drug treatments are available, many have intractable 
symptoms that do not recover between acute episodes. One proposed alternative to drug 
treatments is transcranial magnetic stimulation (TMS). To date, many research trials to assess 
effectiveness of TMS for people with symptoms of schizophrenia have been conducted 
worldwide. However, there is a lack of consensus on whether TMS should be recommended to 
be adopted in routine clinical practice. We conducted a systematic review of the literature for 
all relevant randomised controlled trials comparing TMS with sham or standard treatment.  
Forty one trials (1473 participants) survived eligibility criteria and had extractable data. We 
found significant differences in favour of temporoparietal TMS compared with sham TMS for 
global state (7 RCTs, n=224, MD: -0.5, 95% CI: -0.76 to -0.23) and for positive symptoms 
measured on the Positive and Negative Syndrome Scale (5 RCTs, n=127, MD: -6.09, 95% CI: 
-10.95 to -1.22). However, we also found that the quality of trial reporting was frequently sub-
optimal and the risk of bias was unascertainable for many trial aspects, and this led to many 
trials being graded as very low quality evidence. On that basis we were unable to definitively 
support or refute the routine use of TMS in clinical practice. Further definitive trials of TMS with 
rigorous processes and high-quality reporting are needed. 
 
Background   
People with schizophrenia often experience symptoms which fail to fully respond to 
antipsychotic medication. Transcranial magnetic stimulation (TMS) has been proposed as a 
new treatment for people with schizophrenia, especially those who experience persistent 
auditory hallucinations. 
Objectives   
To estimate the effects of TMS alone, compared with sham TMS or with 'standard 
management' and any other comparison interventions in reducing psychotic symptoms 
associated with schizophrenia. 
Search methods   
We searched the Cochrane Schizophrenia Group Trials Register (June 2006, June 2008 and 
April 2013).  
Selection criteria   
We included all randomised controlled trials (RCTs) recruiting at least five participants and 
comparing TMS with sham TMS or any other treatment for people with schizophrenia. 
Data collection and analysis   
We extracted data independently. For dichotomous data we calculated relative risks (RRs) and 
their 95% confidence intervals (CIs). For continuous data, we calculated mean differences (MD) 
and 95% CI. We used a fixed-effect model. We assessed overall quality of the evidence using 
the GRADE approach. 
Main results   
We included 41 studies with 1473 participants in the review. We found significant differences in 
favour of temporoparietal TMS compared to sham TMS for global state measured on the CGI 
scale (7 RCTs, n = 224, MD -0.5, 95% CI -0.76 to -0.23, very low-quality evidence) and 
positive symptoms measured on the PANSS scale (5 RCTs, n = 127, MD -6.09, 95% CI -10.95 
to -1.22, very low-quality evidence, figure 1). Participants experienced significantly more 
headaches in the temporoparietal TMS group (10 RCTs, n = 392, RR 2.65, 95% CI 1.56 to 
4.50, very low-quality evidence, figure 2). However, no more participants left the study early 
from the TMS group than from the sham group (very low-quality evidence). Cognitive state was 
assessed using 39 different measures, and all were equivocal (very low-quality evidence). 
We included only 2 trials which compared temporoparietal TMS with standard treatment. In 
both trials the participants received first- and second-generation antipsychotic medication in 
both treatment groups, therefore TMS was used an adjunctive therapy to medication. We 
found no significant differences in the number of participants that showed clinical improvement 
in global state (1 RCT, n = 100, RR 1.19, 95% CI 0.91 to 1.57) or left the study early (2 RCTs, 
n = 140, RR 0.33, 95% CI 0.08 to 1.46) (both very low-quality evidence). No studies reported 
on global state score, mental state, cognitive state and adverse effects. 
For prefrontal TMS compared to sham TMS, global state was measured on three different 
scales, all of which presented equivocal results (very low quality evidence). We could not pool 
data for mental state on the PANSS scale due to high heterogeneity. Cognitive state was 
assessed using 19 different measures, with 15/19 being equivocal (very low-quality evidence). 
Prefrontal TMS caused more headaches (6 RCTs, n = 164, RR 2.77, 95% CI 1.22 to 6.26, very 
low-quality evidence) but there was no difference in the number of participants leaving the 
study early (very low-quality evidence). No studies reported data for clinical improvement. 
We found a significant difference in favour of prefrontal theta burst stimulation TMS compared 
to sham TMS for mental state on the PANSS scale (3 RCTs, n = 108, MD -5.71, 95% CI -9.32 
to -2.10, very low evidence). We found no difference for clinical improvement, cognitive state, 
number of headaches, and leaving the study early (very low-quality evidence). 
None of the included studies reported satisfaction with care. 
Authors' conclusions   
Based on this review, there is insufficient evidence to support or refute the use of TMS to treat 
symptoms of schizophrenia. Although some evidence suggests that TMS, and in particular 
temporoparietal TMS, may improve certain symptoms (such as auditory hallucinations and 
positive symptoms of schizophrenia) compared to sham TMS, the results were not robust 
enough to be unequivocal across the assessment measures used. There was insufficient 
evidence to suggest any added benefit with TMS used as an adjunctive therapy to 
antipsychotic medication. 
The overall quality of evidence was graded as very low due to risk of bias, and this was 
accompanied by an imprecision in estimates due to the relatively small number of participants 
in the studies. Thus, consideration is required in improving the quality of trial processes, as 
well as the quality of reporting of ongoing and future TMS trials, so as to facilitate accurate 
future judgements in assessing risk of bias. Differences in TMS techniques in relation to 
stimulation intensity, stimulation length, brain areas stimulated and variations in the design of 
sham TMS contributed to the heterogeneity of study findings, and limited the interpretation and 
applicability of the results. In addition, the trials assessed their outcomes with a variety of 
scales, and usable data were limited. Therefore, to better evaluate the treatment effects of 
TMS in people with schizophrenia, we favour the use of standardised treatment protocols and 
outcome measures. Full details are reported in the Cochrane review (Dougall 2015).  
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Figure 1.  Comparison: Temporoparietal TMS vs sham TMS 
Outcome: Mental state: General - average total score (various scales) 
 
 
 
Figure 2.  Comparison: Temporoparietal TMS vs sham TMS 
Outcome: Adverse effects: Headache 
 
 
